1-5 of 5
Helen Won
Close
Sort by
Journal Articles

Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study

Jennifer R. Brown, Sai Prasad Desikan, Bastien Nguyen, Helen Won, Shady I. Tantawy, Samuel McNeely, Narasimha Marella, Kevin Ebata, Jennifer A. Woyach, Krish Patel, Constantine S. Tam, Toby A. Eyre, Chan Y. Cheah, Nirav N. Shah, Paolo Ghia, Wojciech Jurczak, Minna Balbas, Binoj Nair, Paolo Abada, Chunxiao Wang, Ying (Denise) Wang, Lindsey E. Roeker, Varsha Gandhi, William G. Wierda
Journal: Blood
Blood (2023) 142 (Supplement 1): 326.
https://doi.org/10.1182/blood-2023-180143
Published: 2023
Journal Articles

Genomic Analysis of Hairy Cell Leukemia Identifies Novel Recurrent Genetic Alterations

Benjamin H Durham, MD BS, Bartlomiej Getta, FRCPA, FRACP, MBBS, Sascha Dietrich, MD, Justin Taylor, MD, Helen Won, PhD, James M. Bogenberger, PhD, Sasynia N Scott, PhD, Eunhee Kim, PhD, Young Rock Chung, MS, Stephen S. Chung, MD, Jennifer Hüllein, PhD, Tatjana Walther, PhD, Lu Wang, PhD, Sydney X. Lu, MDPhD, Christopher C. Oakes, PhD, Raoul Tibes, MD PhD, Torsten Haferlach, MD, Barry S Taylor, PhD, Martin S. Tallman, MD, Michael F. Berger, PhD, Jae H. Park, MD, Thorsten Zenz, MD, Omar Abdel-Wahab, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2994.
https://doi.org/10.1182/blood.V130.Suppl_1.2994.2994
Published: 2017
Journal Articles

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

Brief Report
Benjamin H. Durham, Bartlomiej Getta, Sascha Dietrich, Justin Taylor, Helen Won, James M. Bogenberger, Sasinya Scott, Eunhee Kim, Young Rock Chung, Stephen S. Chung, Jennifer Hüllein, Tatjana Walther, Lu Wang, Sydney X. Lu, Christopher C. Oakes, Raoul Tibes, Torsten Haferlach, Barry S. Taylor, Martin S. Tallman, Michael F. Berger, Jae H. Park, Thorsten Zenz, Omar Abdel-Wahab
Journal: Blood
Blood (2017) 130 (14): 1644–1648.
https://doi.org/10.1182/blood-2017-01-765107
Published: 2017
Includes: Supplemental data
Journal Articles

Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MS, Helen Won, MS, Eunhee Kim, PhD, Alan Saven, MD, Martha Wadleigh, MD, Richard M. Stone, MD, Jacqueline C. Barrientos, MD, Kanti R. Rai, MD, Michael R. Grever, MD, Jessica K. Altman, MD, Mario E Lacouture, MD, Neal Rosen, MD PhD, Michael Berger, PhD, Ross L Levine, MD, Omar Abdel-Wahab, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2014) 124 (21): 24.
https://doi.org/10.1182/blood.V124.21.24.24
Published: 2014
Journal Articles

Phase II Trial Of The BRAF Inhibitor, Vemurafenib, In Patients With BRAF Mutant Relapsed Or Refractory Hairy Cell Leukemia

Jae H Park, MD, Stephen S. Chung, MD, Young Rock Chung, MSc, Helen Won, MS, Julie Teruya-Feldstein, MD, Michael Berger, PhD, Talal T Khawaja, BS, Mario E Lacouture, MD, Ross L. Levine, MD, Omar Abdel-Wahab, MD, Martin S Tallman, MD
Journal: Blood
Blood (2013) 122 (21): 2876.
https://doi.org/10.1182/blood.V122.21.2876.2876
Published: 2013